Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one ...
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update — Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim, first-in-human clinical data from the ongoing Phase 1 trial of WTX-330 in the second quarter of 2024 — — Multiple presentations of preclinical data demonstrate the potential of the PREDATORTM platform, including in immunology-based diseases — — Company announces cash runway extension through at least th...
EME Equity Market – April 2024 Market performance – green across all geographies, with Turkey outperforming. The MSCI EM Europe Index was up 5.3% mom in EUR terms and 4.2% mom in USD in April; while the Turkish ISE30 saw the strongest performance, adding 11.6% mom; followed by the Hungarian BUX (+5.0% mom); the Czech PX (+2.8% mom); the Greek ASE (+1.8% mom), the Polish WIG20 (+1.2% mom) and the Romanian BET (+0.1% mom) (all in EUR terms).
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT. To join the listen-only conference call webcast, click the link on the of Agilent’s investor relations website. A recording of the call will also be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory tec...
Veru to Present at the GLP-1 Based Therapeutics Summit MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA. Presentation details: Advancing Enobosarm, An Oral Novel Selective Androgen Receptor Modulator (...
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that m...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO . McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. This press release features multimedia. View the full release here: Padraig McDonnell (Photo: Business Wire) “It’s an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life,” McDonnell said. ...
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update. The audio webcast will be accessible un...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development. The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations ranging from three to five lasers and support for up to 73 high-quality detectors. It meets researchers’ needs for sophisticated, large-...
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss -- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6. “We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect. “Simon’s deep technical knowledge, his broad range of experience, and his career-long focus on strategy, continuous improvement and operational excellence are critical additions to...
Esperion to Participate in Upcoming May Investor Conferences ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations . JMP Securities’ Life Sciences Conference in New York on May 13, 2024, at 2:30 p.m. ET. Bank of America Securities’ 2024 Health Care Conference in Las Vegas on May 15, 2024, at 3:00 p.m. PT / 6:00 p.m. ET. H.C. Wainwright’s 2nd Annual BioConnect Investor Conference in New York on May ...
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Or...
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatmen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.